{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:50:07Z","timestamp":1762375807278},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090116","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T21:58:01Z","timestamp":1393624681000},"page":"e90116","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Abrogation of TNF\u03b1 Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12"],"prefix":"10.1371","volume":"9","author":[{"given":"Bibiana","family":"Barrios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia S.","family":"Baez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Della","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Cejas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cecilia","family":"Rodriguez-Galan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"ref1","volume":"941","unstructured":"Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, <etal>et al<\/etal>.. (2001) The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci <volume>941<\/volume>: : 177\u2013184. PubMed: 11594571."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V99.1.67","article-title":"Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma","volume":"99","author":"SM Ansell","year":"2002","journal-title":"Blood"},{"key":"ref3","volume":"13","unstructured":"Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, <etal>et al<\/etal>.. (2007) Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res <volume>13<\/volume>: : 215\u2013222. PubMed: 17200357."},{"key":"ref4","volume":"5","unstructured":"Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, <etal>et al<\/etal>.. (2007) Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease &lt; 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.J Transl Med <volume>5<\/volume>: : 66. doi: 10.1186\/1479-5876-5-66. PM:18076766."},{"key":"ref5","volume":"27","unstructured":"Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, <etal>et al<\/etal>.. (2007) Treatment of AIDS-related Kaposi&apos;s sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit Rev Immunol <volume>27<\/volume>: : 401\u2013414. PubMed: 18197804."},{"key":"ref6","volume":"5","unstructured":"Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, <etal>et al<\/etal>.. (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res <volume>5<\/volume>: : 3983\u20133989. PubMed: 10632329."},{"key":"ref7","volume":"9","unstructured":"Mazzolini G, Prieto J, Melero I (2003) Gene therapy of cancer with interleukin-12. Curr Pharm Des <volume>9<\/volume>: : 1981\u20131991. doi: 10.2174\/1381612033454261. PubMed: 12871184."},{"key":"ref8","volume":"87","unstructured":"Sgadari C, Angiolillo AL, Tosato G (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood <volume>87<\/volume>: : 3877\u20133882. PubMed: 8611715."},{"key":"ref9","volume":"3","unstructured":"Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol <volume>3<\/volume>: : 133\u2013146. PubMed: 12563297."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4049\/jimmunol.0804166","article-title":"Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity","volume":"183","author":"MC Rodriguez-Galan","year":"2009","journal-title":"J Immunol"},{"key":"ref11","volume":"101","unstructured":"Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, <etal>et al<\/etal>.. (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest <volume>101<\/volume>: : 1441\u20131452. PubMed: 9502787."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","article-title":"Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma","volume":"26","author":"AI Daud","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref13","volume":"8","unstructured":"Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, <etal>et al<\/etal>.. (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2\/neu-expressing malignancies. Mol Cancer Ther <volume>8<\/volume>: : 2983\u20132991. doi:10.1158\/1535-7163.MCT-09-0820. PubMed: 19887543."},{"key":"ref14","volume":"13","unstructured":"Hallaj-Nezhadi S, Lotfipour F, Dass C (2010) Nanoparticle-mediated interleukin-12 cancer gene therapy. J Pharm Pharm Sci <volume>13<\/volume>: : 472\u2013485. PubMed: 21092717."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1479-5876-9-198","article-title":"Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate","volume":"9","author":"CL Chiang","year":"2011","journal-title":"J Transl Med"},{"key":"ref16","volume":"175","unstructured":"Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL (2005) IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis. J Immunol <volume>175<\/volume>: : 5885\u20135894. PubMed: 16237081."},{"key":"ref17","volume":"3","unstructured":"Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, <etal>et al<\/etal>.. (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res <volume>3<\/volume>: : 409\u2013417. PubMed: 9815699."},{"key":"ref18","volume":"147","unstructured":"Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, <etal>et al<\/etal>.. (1995) Role of interferon-gamma in interleukin 12-induced pathology in mice. Am J Pathol <volume>147<\/volume>: : 1693\u20131707. PubMed: 7495294"},{"key":"ref19","volume":"96","unstructured":"Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, <etal>et al<\/etal>.. (2000) Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood <volume>96<\/volume>: : 1465\u20131473. PubMed: 10942393."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jgm.201","article-title":"Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo","volume":"3","author":"VW Lui","year":"2001","journal-title":"J Gene Med"},{"key":"ref21","volume":"8","unstructured":"Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, <etal>et al<\/etal>.. (2001) Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther <volume>8<\/volume>: : 259\u2013267. PubMed: 11313799."},{"key":"ref22","volume":"86","unstructured":"Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, <etal>et al<\/etal>.. (2006) Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest <volume>86<\/volume>: : 254\u2013261. doi:10.1038\/labinvest.3700388. PubMed: 16446706."},{"key":"ref23","volume":"162","unstructured":"Tsuji H, Mukaida N, Harada A, Kaneko S, Matsushita E, <etal>et al<\/etal>.. (1999) Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-gamma-deficient mice by a concomitant reduction of TNF-alpha, IL-12, and IL-18 production. J Immunol <volume>162<\/volume>: : 1049\u20131055. PubMed: 9916732."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archsurg.1990.01410130026003","article-title":"Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis","volume":"125","author":"JL Mayoral","year":"1990","journal-title":"Arch Surg"},{"key":"ref25","volume":"175","unstructured":"Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, <etal>et al<\/etal>.. (1992) T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med <volume>175<\/volume>: : 91\u201398. PubMed: 1730929."},{"key":"ref26","volume":"174","unstructured":"Rodriguez-Galan MC, Bream JH, Farr A, Young HA (2005) Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1\/Th2 cytokine expression. J Immunol <volume>174<\/volume>: : 2796\u20132804. PubMed: 15728489."},{"key":"ref27","volume":"27","unstructured":"Bastos KR, Barboza R, Sardinha L, Russo M, Alvarez JM, <etal>et al<\/etal>.. (2007) Role of endogenous IFN-gamma in macrophage programming induced by IL-12 and IL-18. J Interferon Cytokine Res <volume>27<\/volume>: : 399\u2013410. doi:10.1089\/jir.2007.0128. PubMed: 17523872."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/SHK.0b013e318257114e","article-title":"Generation of nitric oxide and reactive oxygen species by neutrophils and monocytes from septic patients and association with outcomes","volume":"38","author":"SS Santos","year":"2012","journal-title":"Shock"},{"key":"ref29","volume":"14","unstructured":"Lange M, Enkhbaatar P, Nakano Y, Traber DL (2009) Role of nitric oxide in shock: the large animal perspective. Front Biosci <volume>14<\/volume>: : 1979\u20131989. doi:10.2741\/3357. PubMed: 19273179."},{"key":"ref30","volume":"6","unstructured":"Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, <etal>et al<\/etal>.. (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res <volume>6<\/volume>: : 1678\u20131692. PubMed: 10815886."},{"key":"ref31","volume":"4","unstructured":"Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, <etal>et al<\/etal>.. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res <volume>4<\/volume>: : 1183\u20131191. PubMed: 9607576."},{"key":"ref32","volume":"9","unstructured":"Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, <etal>et al<\/etal>.. (2003) Repeated administration of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN\u03b3, umor necrosis factor-a, IL-6 and IL-8 responses. Clin Cancer Res <volume>9<\/volume>: : 76\u201383. PubMed: 12538454."},{"key":"ref33","volume":"7","unstructured":"Egilmez NK, Kilinc MO, Gu T, Conway TF (2007) Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets <volume>7<\/volume>: : 266\u2013270. PubMed: 18220947."},{"key":"ref34","volume":"22","unstructured":"Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, <etal>et al<\/etal>.. (1999) Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother <volume>22<\/volume>: : 135\u2013144. PubMed: 10093038."},{"key":"ref35","volume":"164","unstructured":"Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, <etal>et al<\/etal>.. (2000) IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol <volume>164<\/volume>: : 3330\u20133336. PubMed: 10706727."},{"key":"ref36","volume":"109","unstructured":"Taniguchi H, Shibagaki K, Seshimo K, Kobayashi K (2012) A case of alcoholic hepatitis diagnosed by a liver biopsy and successfully treated by corticosteroid therapy. Nihon Shokakibyo Gakkai Zasshi <volume>109<\/volume>: : 630\u2013637. PubMed: 22481265."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cgh.2012.01.020","article-title":"Association between puberty and features of nonalcoholic fatty liver disease","volume":"10","author":"A Suzuki","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref38","volume":"438","unstructured":"Huerre MR, Lan NT, Marianneau P, Hue NB, Khun H, <etal>et al<\/etal>.. (2001) Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children. Virchows Arch <volume>438<\/volume>: : 107\u2013115. PubMed: 11253111."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/lt.21375","article-title":"Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation","volume":"14","author":"A Errico-Grigioni","year":"2008","journal-title":"Liver Transpl"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T16:08:25Z","timestamp":1540224505000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090116"}},"subtitle":[],"editor":[{"given":"Irving Coy","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090116","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}